Aptinyx Inc. (APTX)
| Market Cap | 152.36M |
| Revenue (ttm) | 1.26M |
| Net Income (ttm) | -56.87M |
| Shares Out | 67.38M |
| EPS (ttm) | -0.95 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 165,678 |
| Open | 2.20 |
| Previous Close | 2.22 |
| Day's Range | 2.16 - 2.26 |
| 52-Week Range | 2.15 - 4.73 |
| Beta | 1.36 |
| Analysts | Strong Buy |
| Price Target | 10.29 (+357.3%) |
| Est. Earnings Date | Nov 11, 2021 |
About APTX
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial ...
Financial Performance
In 2020, Aptinyx's revenue was $1.56 million, a decrease of -57.37% compared to the previous year's $3.67 million. Losses were -$50.05 million, -12.81% less than in 2019.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for Aptinyx stock is "Strong Buy." The 12-month stock price forecast is 10.29, which is an increase of 357.33% from the latest price.
News
Aptinyx to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021
EVANSTON, Ill--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today...
Aptinyx Appoints Gilmore O'Neill, M.B., M.M.Sc., to Board of Directors
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announce...
Aptinyx to Participate in 2021 Cantor Virtual Global Healthcare Conference
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...
Aptinyx Secures $50 Million Growth Capital Credit Facility from K2 HealthVentures
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...
Aptinyx to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announce...
CORRECTING and REPLACING Aptinyx Reports Second Quarter 2021 Financial Results and Business Highlights
EVANSTON, Ill.--(BUSINESS WIRE)--In the Condensed Balance Sheet, last line should read: Total liabilities and stockholders' equity $ 134,168 $ 150,606 instead of: Total liabilities and stockholders'...
Aptinyx Reports Second Quarter 2021 Financial Results and Business Highlights
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported...
Aptinyx to Participate in 2021 Wedbush PacGrow Healthcare Virtual Conference
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announce...
Aptinyx to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announce...
Aptinyx to Participate in William Blair Biotech Focus Conference 2021
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announce...
Aptinyx Stock Looks Promising If You're Willing to Be Patient
When you're shopping for ground-floor biotech opportunities, it pays to be patient and diligent. APTX stock is looking good here.
Aptinyx to Participate in Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announce...
Aptinyx to Participate in Upcoming Investor Conferences
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announce...
Aptinyx Provides Updates On Mid-Stage NYX-783 Program In PTSD Patients
After a Type C meeting with the FDA, Aptinyx Inc (NASDAQ: APTX) has finalized the design of its Phase 2b program for NYX-783 in patients with post-traumatic stress disorder (PTSD). The program will cons...
Aptinyx Provides Update on NYX-783 Development Program for the Treatment of Post-Traumatic Stress Disorder
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announce...
Best Growth Penny Stocks for 2021, Are Small-Caps Worth Watching?
Top growth penny stocks to watch this year? Check these 3 out right now The post Best Growth Penny Stocks for 2021, Are Small-Caps Worth Watching?
Aptinyx Reports First Quarter 2021 Financial Results and Highlights
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported...
Aptinyx Appoints Joan W. Miller, M.D.
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...
Aptinyx to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...
Aptinyx Presents Additional Positive Data from Phase 2 Exploratory Study of NYX-783 in PTSD at Society of Biological ...
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...
Aptinyx to Participate in Upcoming Conferences
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...
Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week
5 Penny Stocks To Watch For The Last Week Of April 2021 The post Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS...
Aptinyx Stock Is Trading Higher After Restarting NYX-458 Study In Dementia Associated Cognitive Impairment
Aptinyx Inc (NASDAQ: APTX) has restarted patient screening in a Phase 2 study evaluating NYX-458 in patients with mild cognitive impairment and mild dementia associated with Parkinson's disease and deme...
Aptinyx Recommences Phase 2 Study of NYX-458 in Patients with Cognitive Impairment Associated with Parkinson's Diseas...
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...
Aptinyx Inc. (APTX) Reports Q4 Loss, Lags Revenue Estimates
Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 16.67% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?